Invariant NKT cells are more abundant in peanut-allergic adults and a subset of CD8 ⁺ iNKT cells are depleted after peanut oil exposure.

Autor: Hopkins GV; School of Life Sciences, The University of Nottingham, Nottingham, United Kingdom., Cochrane S; Safety and Environmental Assurance Centre (SEAC), Unilever, Bedford, United Kingdom., Onion D; School of Life Sciences, The University of Nottingham, Nottingham, United Kingdom., Fairclough LC; School of Life Sciences, The University of Nottingham, Nottingham, United Kingdom.

Publikováno v: Frontiers in immunology [Front Immunol] 2023 Nov 03; Vol. 14, pp. 1293158. Date of Electronic Publication: 2023 Nov 03 (Print Publication: 2023).

Anilinoquinazoline inhibitors of the RET kinase domain-Elaboration of the 7-position.

Autor: Jordan AM; Drug Discovery Unit, Cancer Research UK Manchester Institute, University of Manchester, Wilmslow Road, Manchester M20 4BX, UK., Begum H; Drug Discovery Unit, Cancer Research UK Manchester Institute, University of Manchester, Wilmslow Road, Manchester M20 4BX, UK., Fairweather E; Drug Discovery Unit, Cancer Research UK Manchester Institute, University of Manchester, Wilmslow Road, Manchester M20 4BX, UK., Fritzl S; Drug Discovery Unit, Cancer Research UK Manchester Institute, University of Manchester, Wilmslow Road, Manchester M20 4BX, UK., Goldberg K; Drug Discovery Unit, Cancer Research UK Manchester Institute, University of Manchester, Wilmslow Road, Manchester M20 4BX, UK., Hopkins GV; Drug Discovery Unit, Cancer Research UK Manchester Institute, University of Manchester, Wilmslow Road, Manchester M20 4BX, UK., Hamilton NM; Drug Discovery Unit, Cancer Research UK Manchester Institute, University of Manchester, Wilmslow Road, Manchester M20 4BX, UK., Lyons AJ; Drug Discovery Unit, Cancer Research UK Manchester Institute, University of Manchester, Wilmslow Road, Manchester M20 4BX, UK., March HN; Drug Discovery Unit, Cancer Research UK Manchester Institute, University of Manchester, Wilmslow Road, Manchester M20 4BX, UK., Newton R; Drug Discovery Unit, Cancer Research UK Manchester Institute, University of Manchester, Wilmslow Road, Manchester M20 4BX, UK., Small HF; Drug Discovery Unit, Cancer Research UK Manchester Institute, University of Manchester, Wilmslow Road, Manchester M20 4BX, UK., Vishwanath S; Medicinial Chemistry, SAI Life Sciences, Ltd, Pune, India., Waddell ID; Drug Discovery Unit, Cancer Research UK Manchester Institute, University of Manchester, Wilmslow Road, Manchester M20 4BX, UK., Waszkowycz B; Drug Discovery Unit, Cancer Research UK Manchester Institute, University of Manchester, Wilmslow Road, Manchester M20 4BX, UK., Watson AJ; Drug Discovery Unit, Cancer Research UK Manchester Institute, University of Manchester, Wilmslow Road, Manchester M20 4BX, UK., Ogilvie DJ; Drug Discovery Unit, Cancer Research UK Manchester Institute, University of Manchester, Wilmslow Road, Manchester M20 4BX, UK.

Publikováno v: Bioorganic & medicinal chemistry letters [Bioorg Med Chem Lett] 2016 Jun 01; Vol. 26 (11), pp. 2724-9. Date of Electronic Publication: 2016 Mar 30.

Identification of selective inhibitors of RET and comparison with current clinical candidates through development and validation of a robust screening cascade.

Autor: Watson AJ; Cancer Research UK Manchester Institute, Drug Discovery Unit, University of Manchester, Manchester, M20 4BX, UK., Hopkins GV; Cancer Research UK Manchester Institute, Drug Discovery Unit, University of Manchester, Manchester, M20 4BX, UK., Hitchin S; Cancer Research UK Manchester Institute, Drug Discovery Unit, University of Manchester, Manchester, M20 4BX, UK., Begum H; Cancer Research UK Manchester Institute, Drug Discovery Unit, University of Manchester, Manchester, M20 4BX, UK., Jones S; Cancer Research UK Manchester Institute, Drug Discovery Unit, University of Manchester, Manchester, M20 4BX, UK., Jordan A; Cancer Research UK Manchester Institute, Drug Discovery Unit, University of Manchester, Manchester, M20 4BX, UK., Holt S; Cancer Research UK Manchester Institute, Drug Discovery Unit, University of Manchester, Manchester, M20 4BX, UK., March HN; Cancer Research UK Manchester Institute, Drug Discovery Unit, University of Manchester, Manchester, M20 4BX, UK., Newton R; Cancer Research UK Manchester Institute, Drug Discovery Unit, University of Manchester, Manchester, M20 4BX, UK., Small H; Cancer Research UK Manchester Institute, Drug Discovery Unit, University of Manchester, Manchester, M20 4BX, UK., Stowell A; Cancer Research UK Manchester Institute, Drug Discovery Unit, University of Manchester, Manchester, M20 4BX, UK., Waddell ID; Cancer Research UK Manchester Institute, Drug Discovery Unit, University of Manchester, Manchester, M20 4BX, UK., Waszkowycz B; Cancer Research UK Manchester Institute, Drug Discovery Unit, University of Manchester, Manchester, M20 4BX, UK., Ogilvie DJ; Cancer Research UK Manchester Institute, Drug Discovery Unit, University of Manchester, Manchester, M20 4BX, UK.

Publikováno v: F1000Research [F1000Res] 2016 May 26; Vol. 5, pp. 1005. Date of Electronic Publication: 2016 May 26 (Print Publication: 2016).

The discovery of 2-substituted phenol quinazolines as potent RET kinase inhibitors with improved KDR selectivity.

Autor: Newton R; Cancer Research UK Manchester Institute, Drug Discovery Unit, University of Manchester, Wilmslow Road, Withington, Manchester, M20 4BX, England, UK. Electronic address: rebecca.newton@cruk.manchester.ac.uk., Bowler KA; Cancer Research UK Manchester Institute, Drug Discovery Unit, University of Manchester, Wilmslow Road, Withington, Manchester, M20 4BX, England, UK., Burns EM; Structural Biology Laboratory, Cancer Research UK London Research Institute, London, WC2A 3LY, England, UK., Chapman PJ; Cancer Research UK Manchester Institute, Drug Discovery Unit, University of Manchester, Wilmslow Road, Withington, Manchester, M20 4BX, England, UK., Fairweather EE; Cancer Research UK Manchester Institute, Drug Discovery Unit, University of Manchester, Wilmslow Road, Withington, Manchester, M20 4BX, England, UK., Fritzl SJR; Cancer Research UK Manchester Institute, Drug Discovery Unit, University of Manchester, Wilmslow Road, Withington, Manchester, M20 4BX, England, UK., Goldberg KM; Cancer Research UK Manchester Institute, Drug Discovery Unit, University of Manchester, Wilmslow Road, Withington, Manchester, M20 4BX, England, UK., Hamilton NM; Cancer Research UK Manchester Institute, Drug Discovery Unit, University of Manchester, Wilmslow Road, Withington, Manchester, M20 4BX, England, UK., Holt SV; Cancer Research UK Manchester Institute, Drug Discovery Unit, University of Manchester, Wilmslow Road, Withington, Manchester, M20 4BX, England, UK., Hopkins GV; Cancer Research UK Manchester Institute, Drug Discovery Unit, University of Manchester, Wilmslow Road, Withington, Manchester, M20 4BX, England, UK., Jones SD; Cancer Research UK Manchester Institute, Drug Discovery Unit, University of Manchester, Wilmslow Road, Withington, Manchester, M20 4BX, England, UK., Jordan AM; Cancer Research UK Manchester Institute, Drug Discovery Unit, University of Manchester, Wilmslow Road, Withington, Manchester, M20 4BX, England, UK., Lyons AJ; Cancer Research UK Manchester Institute, Drug Discovery Unit, University of Manchester, Wilmslow Road, Withington, Manchester, M20 4BX, England, UK., Nikki March H; Cancer Research UK Manchester Institute, Drug Discovery Unit, University of Manchester, Wilmslow Road, Withington, Manchester, M20 4BX, England, UK., McDonald NQ; Structural Biology Laboratory, Cancer Research UK London Research Institute, London, WC2A 3LY, England, UK; Institute of Structural and Molecular Biology, Department of Biological Sciences, Birkbeck College, Malet Street, London WC1E 7HX, England, UK., Maguire LA; Cancer Research UK Manchester Institute, Drug Discovery Unit, University of Manchester, Wilmslow Road, Withington, Manchester, M20 4BX, England, UK., Mould DP; Cancer Research UK Manchester Institute, Drug Discovery Unit, University of Manchester, Wilmslow Road, Withington, Manchester, M20 4BX, England, UK., Purkiss AG; Structural Biology Laboratory, Cancer Research UK London Research Institute, London, WC2A 3LY, England, UK., Small HF; Cancer Research UK Manchester Institute, Drug Discovery Unit, University of Manchester, Wilmslow Road, Withington, Manchester, M20 4BX, England, UK., Stowell AIJ; Cancer Research UK Manchester Institute, Drug Discovery Unit, University of Manchester, Wilmslow Road, Withington, Manchester, M20 4BX, England, UK., Thomson GJ; Cancer Research UK Manchester Institute, Drug Discovery Unit, University of Manchester, Wilmslow Road, Withington, Manchester, M20 4BX, England, UK., Waddell ID; Cancer Research UK Manchester Institute, Drug Discovery Unit, University of Manchester, Wilmslow Road, Withington, Manchester, M20 4BX, England, UK., Waszkowycz B; Cancer Research UK Manchester Institute, Drug Discovery Unit, University of Manchester, Wilmslow Road, Withington, Manchester, M20 4BX, England, UK., Watson AJ; Cancer Research UK Manchester Institute, Drug Discovery Unit, University of Manchester, Wilmslow Road, Withington, Manchester, M20 4BX, England, UK., Ogilvie DJ; Cancer Research UK Manchester Institute, Drug Discovery Unit, University of Manchester, Wilmslow Road, Withington, Manchester, M20 4BX, England, UK.

Publikováno v: European journal of medicinal chemistry [Eur J Med Chem] 2016 Apr 13; Vol. 112, pp. 20-32. Date of Electronic Publication: 2016 Jan 29.

Toxoflavins and deazaflavins as the first reported selective small molecule inhibitors of tyrosyl-DNA phosphodiesterase II.

Autor: Raoof A; Paterson Institute for Cancer Research, University of Manchester, Wilmslow Road, Manchester M20 4BX, U.K. araoof@picr.man.ac.uk., Depledge P, Hamilton NM, Hamilton NS, Hitchin JR, Hopkins GV, Jordan AM, Maguire LA, McGonagle AE, Mould DP, Rushbrooke M, Small HF, Smith KM, Thomson GJ, Turlais F, Waddell ID, Waszkowycz B, Watson AJ, Ogilvie DJ

Publikováno v: Journal of medicinal chemistry [J Med Chem] 2013 Aug 22; Vol. 56 (16), pp. 6352-70. Date of Electronic Publication: 2013 Jul 31.